TGA Approval

NUCALA mepolizumab 100 mg powder for injection (232028)

ARTG ID

232028

ARTG Name

NUCALA mepolizumab 100 mg powder for injection

Sponsor

GlaxoSmithKline Australia Pty Ltd

ARTG Date

February 2, 2016

Registration Type

Medicine

Therapeutic Good Type

Medicine

Licence Status

Active

Licence Category

Registered

Sponsor Information

Sponsor Name

Sponsor Item Name

GLAXOSMITHKLINE AUSTRALIA PTY LTD

http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2016-CMI-01284-1

http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2016-PI-01215-1

Ingredient Name

Mepolizumab

Empowering clinical research with data-driven insights and AI-powered tools.

NUCALA mepolizumab 100 mg powder for injection (232028) - TGA 批准文号 | MedPath